Reduced Intensity Transplant Using Extracorporeal Photopheresis

You may be eligible if

• Weight \> 25 kg
• Patients with acute lymphoblastic leukemia (ALL) who are in CR (complete remission; \< 5% blasts in bone marrow and no active central nervous system disease) who:
• * Are in second remission with an initial remission of \< 36 months.
• * Patients with "high risk" disease in CR1, defined by karyotype abnormalities such as presence of (9;22) translocation, monosomy 7, or monosomy 5; and/or patients with slow initial response (initial remission not reached within four weeks from diagnosis).
• * Are in third (or subsequent) remission
• * Experience isolated extramedullary relapse while on therapy
• * Have experienced relapse following myeloablative stem cell transplant
• * Are WT1+ following induction therapy
• Patients with acute myelogenous leukemia (AML) who:
• * Are in first remission and remain WT1 positive.
• * Are in second remission
• * Are in initial partial remission (\< 20% blasts in bone marrow)
• * Experience relapse following myeloablative stem cell transplant
• Patients with relapsed lymphoma whose residual disease appears to be chemo-responsive and non-bulky (\< 5 cm largest diameter)
• Patients with chronic myelogenous leukemia (CML) in chronic phase who:
• * Don't achieve remission (molecular or cytogenetic) by 1 year of diagnosis with therapy (imatinib mesylate or interferon)
• * Have a rising quantitative bcr/abl on imatinib mesylate (molecular relapse)
• * Had developed accelerated phase regardless of therapy but are now back in second chronic phase
• Patients with recurrent solid tumors (neuroblastoma, Ewing's sarcoma, melanoma, rhabdomyosarcoma)
• Patients with myelodysplastic syndrome
• Patients with selected immunodeficiencies such as Wiskott-Aldrich syndrome or hyper-IgM syndrome
• Patients with metabolic diseases such as Niemann-Pick or adrenoleukodystrophy
• Patients with bone marrow failure syndromes, including aplastic anemia
• Adequate venous access